secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2026-02-13T23:59:59+00:00
Accession:  0001193125-26-051815
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics appoints two new directors, expanding board to five
--------------------------------------------------------------------------

- Board increased from 3 to 5 members; Christopher W. Gerry (President & GC) and Phillip B. Donenberg appointed Feb 13, 2026.
- Gerry already serves as President and General Counsel of the company.
- Donenberg brings CFO and audit committee experience from Taysha, Tectonic, Jaguar Gene Therapy, and AveXis.
- Donenberg will receive non-employee director compensation per 2025 proxy statement.
- Each appointee entered standard indemnification agreement with the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526051815/0001193125-26-051815-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526051815/d82134d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-051815

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer